Items Tagged ‘alk’

December 3rd, 2015

Alectinib Produces High Anti-Cancer Activity in Recurrent Lung Cancer

By

The investigative agent, alectinib, produces high anti-cancer responses among patients with non-small cell lung cancer (NSCLC) that have stopped responding to Xalkori™(crizotinib). These results were recently published as a rapid online communication article in the Journal of Clinical Oncology. Lung cancer remains the leading cause of cancer-related deaths in the United States. Non-small cell lung […]

View full entry

Tags: alectinib, alk, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, Recurrent Lung Cancer - Non-Small Cell


November 16th, 2015

New Lab Test Enables Precision Treatment for Lung Cancer

By

The complementary laboratory test that measures PD-L1 levels among patients with lung cancer who are to receive treatment with Opdivo® (nivolumab), is now available for commercial use and can help guide more precise therapy for lung cancer. Lung cancer is the most common cause of cancer-related deaths in the United States. Opdivo, a PD 1 […]

View full entry

Tags: alk, EGFR, General Lung Cancer, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell, opdivo, PD-L1 levels, xalkori


December 6th, 2014

Xalkori™ (crizotinib) Targeted Therapy More Effective Than Chemotherapy for Treatment of Lung Cancer

By

A new drug Xalkori™ (crizotinib) is more beneficial than chemotherapy for certain individuals with lung cancer according to new research published in the New England Journal of Medicine. Lung cancer is the leading cause of cancer death in the U.S. and around the world, highlighting the importance of developing effective new approaches to treatment. Ninety percent […]

View full entry

Tags: alk, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, Recurrent Lung Cancer - Non-Small Cell, Stages I-IIIA Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell, xalkori


August 29th, 2014

Interim Results of X-396 in ALK positive Non-Small Cell Lung Cancer Appear Promising

By

Preliminary results from a small phase 1 study of X-396, a novel anaplastic lymphoma kinase (ALK) inhibitor showed that X-396 is well tolerated and has antitumor activity in patients with ALK positive non-small cell lung cancer (NSCLC). Lung cancer is the leading cause of cancer death in the U.S. and around the world. Up to […]

View full entry

Tags: alk, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, Recurrent Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell, X-396